search
Back to results

EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement

Primary Purpose

Portal Hypertension, Chronic Liver Disease, Cirrhosis

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Transjugular hepatic venous pressure gradient measurement with liver biopsy
Endoscopic ultrasound portal pressure gradient measurement with liver biopsy
Sponsored by
McGill University Health Centre/Research Institute of the McGill University Health Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Portal Hypertension focused on measuring eus-portal pressure gradient, eus-liver biopsies, liver biopsy, portal pressure gradient, hepatic venous pressure gradient, transjugular-portal pressure gradient, Transjugular-Liver biopsies

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age above 18 years
  • Undergoing evaluation for chronic liver disease or portal hypertension
  • Planned to undergo a liver biopsy and HVPG by their treating hepatologist for clinical purposes
  • Signed informed consent

Exclusion Criteria:

  • Uncorrectable coagulopathy (INR above 1.5)
  • Uncorrectable thrombocytopenia (Platelets under 50,000)
  • Anticoagulation or antiplatelet therapy that cannot be discontinued
  • Surgically altered upper digestive anatomy
  • Biliary obstruction
  • Grade II ascites or more
  • Intrahepatic portal vein thrombosis
  • Previous liver transplantation
  • Past hypersensitivity reaction to midazolam or ketamine
  • History of psychotic disorder
  • Pregnancy

Sites / Locations

  • McGill University Health CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Transjugular approach

Endoscopic ultrasound approach

Arm Description

Transjugular hepatic venous pressure gradient measurement with liver biopsy (HVPG-LB).

Endoscopic ultrasound portal pressure gradient measurement with liver biopsy (EUS-PPG-LB)

Outcomes

Primary Outcome Measures

Compare the proportion of adequate Liver Biopsy specimens with reliable portal pressure gradient obtained by TJ or EUS
Liver Biopsy (LB) specimens are defined as a biopsy of at least 25mm in length following formalin fixation and at least 11 complete portal tracts. The Portal pressure gradient (PPG) measurement is defined as two PPG values with less than 2mmHg difference.

Secondary Outcome Measures

Technical success
Compare the proportion of HVPG and LB obtained by TJ or EUS approach
Liver biopsy-related outcomes
Number of adequate liver biopsies obtained, total aggregate length (defined as the sum of the lengths of all specimens following fixation), number of complete portal tracts per specimen, and total number of passes needed.
PPG-related outcomes
Number of PPG obtained, number of reliable PPG obtained
Adverse events
Proportion of adverse events in the TJ and EUS arms following the procedure, at day 7, and day 30.
Satisfaction with sedation
Compare the score obtained on the sedation satisfaction surveys as completed by the participant and the physician within the 2 arms

Full Information

First Posted
October 22, 2021
Last Updated
December 5, 2021
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT05118308
Brief Title
EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
Official Title
Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Gradient Measurement Compared to the Transjugular Approach: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
November 4, 2021 (Actual)
Primary Completion Date
November 4, 2023 (Anticipated)
Study Completion Date
December 4, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will directly compare the endoscopic ultrasound guided approach to obtain adequate liver biopsies and portal pressure gradient measurements to the current standard of care which uses the transjugular approach.
Detailed Description
Current guidelines recommend that when a hepatic venous pressure gradient and a liver biopsy are needed, the liver biopsy should be done by the transjugular approach during the same session. A major limitation is that liver biopsies obtained by the transjugular approach meet quality criteria proposed by the American Association for the Study of Liver Diseases (at least 2-3cm with at least 11 complete portal tracts) in only 40% of cases. Recent studies have shown that endoscopic ultrasound-guided liver biopsy (EUS-LB) can achieve a high rate of adequate liver biopsies using the same strict criteria described above. In addition, a novel endoscopic-ultrasound adapted manometer allows the safe and accurate measurement of portal pressure gradient (PPG) which correlates well with hepatic venous pressures (HVPG) obtained by the transjugular approach. Unfortunately to this day, no randomized controlled trials has compared the EUS-LB and PPG vs TJ-LB and HVPG directly.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Portal Hypertension, Chronic Liver Disease, Cirrhosis
Keywords
eus-portal pressure gradient, eus-liver biopsies, liver biopsy, portal pressure gradient, hepatic venous pressure gradient, transjugular-portal pressure gradient, Transjugular-Liver biopsies

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
As EUS and TJ procedures are inherently different, patients and health-care workers directly involved in the procedure, including nurses, physicians, and technicians, will not be blinded. Pathologists interpreting liver biopsies will be blinded to the intervention group.
Allocation
Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transjugular approach
Arm Type
Experimental
Arm Description
Transjugular hepatic venous pressure gradient measurement with liver biopsy (HVPG-LB).
Arm Title
Endoscopic ultrasound approach
Arm Type
Experimental
Arm Description
Endoscopic ultrasound portal pressure gradient measurement with liver biopsy (EUS-PPG-LB)
Intervention Type
Procedure
Intervention Name(s)
Transjugular hepatic venous pressure gradient measurement with liver biopsy
Intervention Description
This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
Intervention Type
Procedure
Intervention Name(s)
Endoscopic ultrasound portal pressure gradient measurement with liver biopsy
Intervention Description
A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
Primary Outcome Measure Information:
Title
Compare the proportion of adequate Liver Biopsy specimens with reliable portal pressure gradient obtained by TJ or EUS
Description
Liver Biopsy (LB) specimens are defined as a biopsy of at least 25mm in length following formalin fixation and at least 11 complete portal tracts. The Portal pressure gradient (PPG) measurement is defined as two PPG values with less than 2mmHg difference.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Technical success
Description
Compare the proportion of HVPG and LB obtained by TJ or EUS approach
Time Frame
1 day
Title
Liver biopsy-related outcomes
Description
Number of adequate liver biopsies obtained, total aggregate length (defined as the sum of the lengths of all specimens following fixation), number of complete portal tracts per specimen, and total number of passes needed.
Time Frame
2 weeks
Title
PPG-related outcomes
Description
Number of PPG obtained, number of reliable PPG obtained
Time Frame
1 day
Title
Adverse events
Description
Proportion of adverse events in the TJ and EUS arms following the procedure, at day 7, and day 30.
Time Frame
30 days
Title
Satisfaction with sedation
Description
Compare the score obtained on the sedation satisfaction surveys as completed by the participant and the physician within the 2 arms
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age above 18 years Undergoing evaluation for chronic liver disease or portal hypertension Planned to undergo a liver biopsy and HVPG by their treating hepatologist for clinical purposes Signed informed consent Exclusion Criteria: Uncorrectable coagulopathy (INR above 1.5) Uncorrectable thrombocytopenia (Platelets under 50,000) Anticoagulation or antiplatelet therapy that cannot be discontinued Surgically altered upper digestive anatomy Biliary obstruction Grade II ascites or more Intrahepatic portal vein thrombosis Previous liver transplantation Past hypersensitivity reaction to midazolam or ketamine History of psychotic disorder Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amine Benmassaoud, MD
Phone
514-843-1421
Email
amine.benmassaoud@mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Yen-I Chen, MD
Phone
514-843-1421
Email
yeni.chen@mcgill.ca
Facility Information:
Facility Name
McGill University Health Centre
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3G1A4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amine Benmassaoud, MD
Phone
5148431421
Email
amine.benmassaoud@mcgill.ca
First Name & Middle Initial & Last Name & Degree
Yen-I Chen, MD
Phone
5148431421
Email
yeni.chen@mcgill.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement

We'll reach out to this number within 24 hrs